I like the thinking outside the box.
the risks regarding a competitor(is new drug or mechanism) is much less so. As a drug that is made from scratch or just discovered to do something still has to go through the whole drug process, unless they find a drug like bisantrene that has already been through trials in the past. Certainly possible, highly improbable but I guess a risk all the same.
over expressed cancer becoming resistant would be an issue for the acquirer of the drug I would assume, as I assume that would be something over time.
being poached is possible, but if all board sees things the same as Dr T, I would think they would see so much upside it would be av step down financially. Obviously taking into consideration the risk.
unfortunately, I can't argue whether Dr T is delusional or not... I'll just leave that as a risk
MST valuation of RAC, page-174
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.82 |
Change
0.010(0.55%) |
Mkt cap ! $309.3M | |||
| Open | High | Low | Value | Volume |
| $1.81 | $1.85 | $1.75 | $154.4K | 85.93K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4739 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.83 | 7500 | 1 |
View Market Depth
| Last trade - 15.52pm 26/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |